Metraipolis › archive › dc_bdad8cb8e5cc

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007) — Europe PMC PMID:42198399

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42198399
DOI
10.3390/ph19050724
License (as archived)
solo-consultazione
Archived
2026-11-02T20:49:04.259Z
SHA-256 of the archived text
6a0a50895c0dcc29b8a36a56d6316c6e927a6835f6b6173361daffcc1224081d
Stable URL of this page
https://metraipolis.com/documento/dc_bdad8cb8e5cc

How to cite

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007) — Europe PMC PMID:42198399 — Europe PMC (en), https://europepmc.org/article/MED/42198399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bdad8cb8e5cc (Metraipolis archive dc_bdad8cb8e5cc, sha256 6a0a50895c0dcc29b8a36a56d6316c6e927a6835f6b6173361daffcc1224081d)
BibTeX
@misc{dcbdad8cb8e5cc,
  title = {A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007) — Europe PMC PMID:42198399},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42198399},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bdad8cb8e5cc; sha256 6a0a50895c0dcc29b8a36a56d6316c6e927a6835f6b6173361daffcc1224081d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42198399. Agents can read the archived copy with the MCP tool read_document.